InterCure resolves Nasdaq minimum-bid-price deficiency
InterCure ($INCR) received written confirmation that it has regained compliance with Nasdaq’s minimum-bid-price requirement. Its shares had closed at or above $1 for ten consecutive business days, allowing Nasdaq to close the specific deficiency. The decision follows an earlier warning that the shares faced delisting after the company failed to regain compliance within the original grace period. The confirmation removes that particular listing obstacle and supersedes the bid-price issue describe
0